Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer.

Guo X, Zhang Y, Mayakonda A, Madan V, Ding LW, Lin LH, Zia S, Gery S, Tyner JW, Zhou W, Yin D, Lin DC, Koeffler HP.

Oncogene. 2018 Jul 6. doi: 10.1038/s41388-018-0371-4. [Epub ahead of print]

PMID:
29980791
2.

Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.

Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.

Biomed Pharmacother. 2018 Mar;99:543-551. doi: 10.1016/j.biopha.2018.01.045. Epub 2018 Feb 20.

PMID:
29902865
3.

Circadian clock cryptochrome proteins regulate autoimmunity.

Cao Q, Zhao X, Bai J, Gery S, Sun H, Lin DC, Chen Q, Chen Z, Mack L, Yang H, Deng R, Shi X, Chong LW, Cho H, Xie J, Li QZ, Müschen M, Atkins AR, Liddle C, Yu RT, Alkan S, Said JW, Zheng Y, Downes M, Evans RM, Koeffler HP.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12548-12553. doi: 10.1073/pnas.1619119114. Epub 2017 Nov 6.

4.

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Masouleh BK, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707. eCollection 2017 Sep 8.

5.

Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.

Takao S, Chien W, Madan V, Lin DC, Ding LW, Sun QY, Mayakonda A, Sudo M, Xu L, Chen Y, Jiang YY, Gery S, Lill M, Park E, Senapedis W, Baloglu E, Müschen M, Koeffler HP.

Leukemia. 2018 Mar;32(3):616-625. doi: 10.1038/leu.2017.281. Epub 2017 Sep 14.

PMID:
28904384
6.

Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia.

Gugliotta G, Sudo M, Cao Q, Lin DC, Sun H, Takao S, Le Moigne R, Rolfe M, Gery S, Müschen M, Cavo M, Koeffler HP.

Neoplasia. 2017 Oct;19(10):750-761. doi: 10.1016/j.neo.2017.08.001. Epub 2017 Aug 29.

7.

Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma.

Sun H, Lin DC, Cao Q, Pang B, Gae DD, Lee VKM, Lim HJ, Doan N, Said JW, Gery S, Chow M, Mayakonda A, Forscher C, Tyner JW, Koeffler HP.

Clin Cancer Res. 2017 Aug 1;23(15):4376-4387. doi: 10.1158/1078-0432.CCR-16-2185. Epub 2017 Mar 23.

8.

Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD.

Chien W, Sun QY, Ding LW, Mayakonda A, Takao S, Liu L, Lim SL, Tan KT, Garg M, De Sousa Maria Varela A, Xiao J, Jacob N, Behrens K, Stocking C, Lill M, Madan V, Hattori N, Gery S, Ogawa S, Wakita S, Ikezoe T, Shih LY, Alpermann T, Haferlach T, Yang H, Koeffler HP.

Leukemia. 2017 Mar;31(3):762-766. doi: 10.1038/leu.2016.343. Epub 2016 Nov 24. No abstract available.

PMID:
27881871
9.

CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.

Sun H, Lin DC, Cao Q, Guo X, Marijon H, Zhao Z, Gery S, Xu L, Yang H, Pang B, Lee VK, Lim HJ, Doan N, Said JW, Chu P, Mayakonda A, Thomas T, Forscher C, Baloglu E, Shacham S, Rajalingam R, Koeffler HP.

Cancer Res. 2016 May 1;76(9):2687-97. doi: 10.1158/0008-5472.CAN-15-1572. Epub 2016 Mar 8.

10.

Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.

Sun H, Lin DC, Guo X, Kharabi Masouleh B, Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, Chien W, Müller-Tidow C, Jing Y, Agelopoulos K, Müschen M, Koeffler HP.

Oncotarget. 2016 Apr 5;7(14):18736-49. doi: 10.18632/oncotarget.7702. Erratum in: Oncotarget. 2017 Sep 8;8(38):64651.

11.

BCOR regulates myeloid cell proliferation and differentiation.

Cao Q, Gearhart MD, Gery S, Shojaee S, Yang H, Sun H, Lin DC, Bai JW, Mead M, Zhao Z, Chen Q, Chien WW, Alkan S, Alpermann T, Haferlach T, Müschen M, Bardwell VJ, Koeffler HP.

Leukemia. 2016 May;30(5):1155-65. doi: 10.1038/leu.2016.2. Epub 2016 Feb 5.

12.

Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.

Garg M, Okamoto R, Nagata Y, Kanojia D, Venkatesan S, M T A, Braunstein GD, Said JW, Doan NB, Ho Q, Akagi T, Gery S, Liu LZ, Tan KT, Chng WJ, Yang H, Ogawa S, Koeffler HP.

J Clin Endocrinol Metab. 2015 Feb;100(2):725-35. doi: 10.1210/jc.2014-2359. Epub 2014 Nov 3.

13.

KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.

Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP.

Cancer Chemother Pharmacol. 2014 Sep;74(3):487-95. doi: 10.1007/s00280-014-2495-8. Epub 2014 Jul 17.

14.

Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.

Chien W, Ding LW, Sun QY, Torres-Fernandez LA, Tan SZ, Xiao J, Lim SL, Garg M, Lee KL, Kitajima S, Takao S, Leong WZ, Sun H, Tokatly I, Poellinger L, Gery S, Koeffler PH.

Oncotarget. 2014 Jul 15;5(13):4881-94.

15.

[Launching of the Academy of Medicine Foundation].

Joly P, Dru JM, Charpentier B, Juillet Y, Scotti JP, Gery S.

Rev Prat. 2014 Apr;64(4):447. French. No abstract available.

PMID:
24855768
16.

LNK (SH2B3): paradoxical effects in ovarian cancer.

Ding LW, Sun QY, Lin DC, Chien W, Hattori N, Dong XM, Gery S, Garg M, Doan NB, Said JW, Xiao JF, Yang H, Liu LZ, Meng X, Huang RY, Tang K, Koeffler HP.

Oncogene. 2015 Mar 12;34(11):1463-74. doi: 10.1038/onc.2014.34. Epub 2014 Apr 7.

17.

Deficiency of CCAAT/enhancer binding protein-epsilon reduces atherosclerotic lesions in LDLR-/- mice.

Okamoto R, Gery S, Gombart AF, Wang X, Castellani LW, Akagi T, Chen S, Arditi M, Ho Q, Lusis AJ, Li Q, Koeffler HP.

PLoS One. 2014 Jan 28;9(1):e85341. doi: 10.1371/journal.pone.0085341. eCollection 2014.

18.

Off-target effects of c-MET inhibitors on thyroid cancer cells.

Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, Phillip Koeffler H.

Mol Cancer Ther. 2014 Jan;13(1):134-43. doi: 10.1158/1535-7163.MCT-13-0187. Epub 2013 Oct 29.

19.

Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.

Garg M, Kanojia D, Okamoto R, Jain S, Madan V, Chien W, Sampath A, Ding LW, Xuan M, Said JW, Doan NB, Liu LZ, Yang H, Gery S, Braunstein GD, Koeffler HP.

J Clin Endocrinol Metab. 2014 Jan;99(1):E62-72. doi: 10.1210/jc.2013-2994. Epub 2013 Dec 20.

20.

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.

Chan D, Zheng Y, Tyner JW, Chng WJ, Chien WW, Gery S, Leong G, Braunstein GD, Koeffler HP.

J Cancer Res Clin Oncol. 2013 Sep;139(9):1507-14. doi: 10.1007/s00432-013-1465-6. Epub 2013 Jul 4.

21.

Novel Gemini vitamin D3 analogs: large structure/function analysis and ability to induce antimicrobial peptide.

Okamoto R, Gery S, Kuwayama Y, Borregaard N, Ho Q, Alvarez R, Akagi T, Liu GY, Uskokovic MR, Koeffler HP.

Int J Cancer. 2014 Jan 1;134(1):207-17. doi: 10.1002/ijc.28328. Epub 2013 Jul 16.

22.

SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.

Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A, Koeffler HP.

Br J Haematol. 2013 Jun;161(6):811-20. doi: 10.1111/bjh.12327. Epub 2013 Apr 17.

23.

The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.

Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW, Koeffler HP.

Int J Cancer. 2013 Jun 15;132(12):2730-7. doi: 10.1002/ijc.27950. Epub 2012 Dec 13.

24.

Role of the adaptor protein LNK in normal and malignant hematopoiesis.

Gery S, Koeffler HP.

Oncogene. 2013 Jun 27;32(26):3111-8. doi: 10.1038/onc.2012.435. Epub 2012 Oct 8. Review.

PMID:
23045270
25.

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.

Lin DC, Yin T, Koren-Michowitz M, Ding LW, Gueller S, Gery S, Tabayashi T, Bergholz U, Kazi JU, Rönnstrand L, Stocking C, Koeffler HP.

Blood. 2012 Oct 18;120(16):3310-7. doi: 10.1182/blood-2011-10-388611. Epub 2012 Aug 31.

26.

Transcription factor CCAAT/enhancer-binding protein alpha and critical circadian clock downstream target gene PER2 are highly deregulated in diffuse large B-cell lymphoma.

Thoennissen NH, Thoennissen GB, Abbassi S, Nabavi-Nouis S, Sauer T, Doan NB, Gery S, Müller-Tidow C, Said JW, Koeffler HP.

Leuk Lymphoma. 2012 Aug;53(8):1577-85. doi: 10.3109/10428194.2012.658792. Epub 2012 Feb 21.

27.

Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling.

Gueller S, Hehn S, Nowak V, Gery S, Serve H, Brandts CH, Koeffler HP.

Exp Hematol. 2011 May;39(5):591-600. doi: 10.1016/j.exphem.2011.02.001. Epub 2011 Mar 1.

PMID:
21310211
28.

Circadian rhythms and cancer.

Gery S, Koeffler HP.

Cell Cycle. 2010 Mar 15;9(6):1097-103. Epub 2010 Mar 15. Review.

29.

Per2 is a C/EBP target gene implicated in myeloid leukemia.

Gery S, Koeffler HP.

Integr Cancer Ther. 2009 Dec;8(4):317-20. doi: 10.1177/1534735409352084. Epub 2009 Nov 18.

PMID:
19926610
30.

A role for the clock gene per1 in prostate cancer.

Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP.

Cancer Res. 2009 Oct 1;69(19):7619-25. doi: 10.1158/0008-5472.CAN-08-4199. Epub 2009 Sep 14.

31.
32.

Expression of the adaptor protein Lnk in leukemia cells.

Gery S, Gueller S, Nowak V, Sohn J, Hofmann WK, Koeffler HP.

Exp Hematol. 2009 May;37(5):585-592.e2. doi: 10.1016/j.exphem.2009.01.009.

PMID:
19375649
33.

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP.

J Leukoc Biol. 2009 Jun;85(6):957-65. doi: 10.1189/jlb.0908575. Epub 2009 Mar 17.

34.

Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells.

Kumagai T, Akagi T, Desmond JC, Kawamata N, Gery S, Imai Y, Song JH, Gui D, Said J, Koeffler HP.

Int J Cancer. 2009 Feb 15;124(4):827-33. doi: 10.1002/ijc.23994.

35.

Adaptor protein Lnk associates with Tyr(568) in c-Kit.

Gueller S, Gery S, Nowak V, Liu L, Serve H, Koeffler HP.

Biochem J. 2008 Oct 15;415(2):241-5. doi: 10.1042/BJ20080102.

PMID:
18588518
36.

The role of circadian regulation in cancer.

Gery S, Koeffler HP.

Cold Spring Harb Symp Quant Biol. 2007;72:459-64. doi: 10.1101/sqb.2007.72.004. Review.

PMID:
18419305
37.

HPP1-mediated tumor suppression requires activation of STAT1 pathways.

Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D.

Int J Cancer. 2008 Apr 1;122(7):1567-72.

38.

Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.

Gery S, Gueller S, Chumakova K, Kawamata N, Liu L, Koeffler HP.

Blood. 2007 Nov 1;110(9):3360-4. Epub 2007 Aug 10.

39.

The clock gene Per2 links the circadian system to the estrogen receptor.

Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP.

Oncogene. 2007 Dec 13;26(57):7916-20. Epub 2007 Jun 18.

PMID:
17599055
40.

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.

Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP.

Int J Cancer. 2007 Aug 1;121(3):656-65.

41.

RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.

Gery S, Park DJ, Vuong PT, Virk RK, Muller CI, Hofmann WK, Koeffler HP.

Exp Hematol. 2007 Apr;35(4):572-8.

42.

Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer.

Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, Marchevsky A, Mckenna R, Taguchi H, Koeffler HP.

Clin Cancer Res. 2007 Mar 1;13(5):1399-404.

43.

Transcription factors in hematopoietic malignancies.

Gery S, Koeffler HP.

Curr Opin Genet Dev. 2007 Feb;17(1):78-83. Epub 2007 Jan 8. Review.

PMID:
17210248
44.

The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells.

Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP.

Mol Cell. 2006 May 5;22(3):375-82.

45.

Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.

Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP.

Clin Cancer Res. 2005 Oct 15;11(20):7243-54.

46.

Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia.

Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP.

Blood. 2005 Oct 15;106(8):2827-36. Epub 2005 Jun 28.

47.

CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.

Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP.

Cancer Res. 2005 Jun 1;65(11):4762-8.

48.

Discovery of epigenetically masked tumor suppressor genes in endometrial cancer.

Takai N, Kawamata N, Walsh CS, Gery S, Desmond JC, Whittaker S, Said JW, Popoviciu LM, Jones PA, Miyakawa I, Koeffler HP.

Mol Cancer Res. 2005 May;3(5):261-9.

49.

Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.

Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP.

Clin Cancer Res. 2005 May 1;11(9):3184-90.

50.

CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model.

Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M, Fishman P.

Neoplasia. 2005 Jan;7(1):85-90.

Supplemental Content

Support Center